Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5-dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes

Chemical Research in Toxicology

Volumn 22, Issue 9, 2009, Pages 1603-1612

  Chen, Hao ^a   Zientek, Michael ^a   Jalaie, Mehran ^a   Zhang, Yanhua ^a   Bigge, Christopher ^a   Mutlib, Abdul ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(N [4 CHLOROPHENYL]CARBAMOYL) GLUTATHIONE; 4 CHLOROPHENYL ANILINE; 4 CHLOROPHENYL ISOCYANATE; 4,5 DIHYDROPYRAZOLE 1 CARBOXYLIC ACID (4 CHLOROPHENYL AMIDE); ANILINE DERIVATIVE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUTATHIONE DERIVATIVE; ISOCYANIC ACID DERIVATIVE; PYRAZOLE; PYRAZOLINE DERIVATIVE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; COMPUTER MODEL; ENZYME ACTIVATION; ENZYME KINETICS; HUMAN; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; OXIDATION; URINALYSIS;

CATALYTIC DOMAIN; CHLOROBENZENES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; HUMANS; ISOCYANATES; KINETICS; MICROSOMES, LIVER; PYRAZOLES; PYRONES; QUANTUM THEORY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

RODENTIA;

EID: 70349345891     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900167y     Document Type: Article

References (45)

1. Lasser, K. E., Allen, P. D., Woolhander, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220.
2. Lee, M. W. (2003) Drug-induced hepatotoxicity. New Engl. J. Med. 349, 474-485.
3. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-716. (Pubitemid 39173511)
4. Hinson, J. A., Pumford, N. R., and Nelson, S. D. (1994) The role of metabolic activation in drug toxicity. Drug Metab. Rev. 26, 395-412. (Pubitemid 24171640)
5. Hinson, J. A., Pumford, N. R., and Roberts, D. W. (1995) Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab. Rev. 27, 73-92.
6. Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Maggs, J. L., and Park, B. K. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283, 1375-1382. (Pubitemid 28016513)
7. Koen, Y. M., and Hanzlik, R. P. (2002) Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene. Chem. Res. Toxicol. 15, 699-706.
8. Baillie, T. A., and Kassahun, K. (2001) Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv. Exp. Med. Biol. 500, 45-71.
9. Park, B. K., Kitteringham, N. P., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2004) The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. pharmacol. Toxicol. 45, 177-202. (Pubitemid 40261802)
10. Baillie, T. A. (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-892.
11. Dahlin, D. C., Miwa, G. T., Lu, A. Y., and Nelson, S. D. (1984) N-acetyl-p-benzoquinone imine: a cytochrome P450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. U.S.A. 81, 1327-1331.
12. Holme, J. A., Dahlin, D. C., Nelson, S. D., and Dybing, E. (1984) Cytotoxic effects of N-acetyl-p-benzoquinone imine, a common arylating intermediate of paracetamol and N-hydroxyparacetamol. Biochem. Pharmacol. 33, 401-406.
13. Lu, A. Y., Miwa, G. T., and Wislocki, P. G. (1988) Toxicological significance of covalently bound drug residue. Rev. Biochem. Toxicol. 9, 1-27.
14. Tirmenstein, M. A., and Nelson, S. D. (1989) Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J. Biol. Chem. 264, 9814-9819.
15. Hinson, J. A., and Roberts, D. W. (1992) Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Annu. Rev. Pharmacol. Toxicol. 32, 471-510.
16. Nelson, S. D. (1995) Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab. Rev. 27, 147-177.
17. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
18. Yan, Z., and Caldwell, G. W. (2004) Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal. Chem. 76, 6835-6847. (Pubitemid 39600854)
19. Gan, J., Harper, T. W., Hsueh, M.-M., Qu, Q., and Humphreys, G. W. (2005) Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18, 896-903. (Pubitemid 40705457)
20. Castro-Perez, J., Plumb, R., Liang, L., and Yang, E. (2005) A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun. Mass Spectrom. 19, 798-804. (Pubitemid 40349420)
21. Mutlib, A., Lam, W., Atherton, J., Chen, H., Galatsis, P., and Stolle, W. (2005) Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites. Rapid Commun. Mass Spectrom. 19, 3482-3492. (Pubitemid 41691924)
22. Chen, H., Zhang, Y.-H., Edmund, J., Bigge, C., and Mutlib, A. (2008) Bioactivation of a dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide) scaffold to a putative p-chlorophenyl isocyanate in rat liver microsomes and in vivo in rats. Chem. Res. Toxicol. 21, 1095-1106.
23. Chen, H., Chen, W., Gan, L.-H., and Mutlib, A. (2003) Metabolism of (S)-5,6-difluoro-4-cyclopropylethnyl-4-trifluoromethyl-3,4-dihydro- 2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes: metabolic activation and enzyme kinetics. Drug Metab. Dispos. 31, 122-132. (Pubitemid 36735266)
24. Gehlhaar, D., Bouzida, D., and Rejto, P. A. (1999) Reduced Dimensionality in Ligand-Protein Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-Directed Combinatorial Libraries, in Rational Drug Design (Parrill, A. L., and Reddy, M. R., Eds.) ACS Symposium Series 719, pp. 292-311, American Chemical Society, Washington, DC. (Pubitemid 129547007)
25. Gehlhaar, D. K., Verkhivker, G. M., Rejto, P. A., Sherman, C. J., Fogel, D. B., Fogel, L. J., and Freer, S. T. (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem. Biol. 2, 317-324.
26. Marrone, T., Luty, B. A., and Rose, P. W. (1999) Discovering High- Affinity Ligands from the Computationally Predicted Structures and Affinities of Small Molecules Bound to a Target: A Virtual Screening Approach, in Virtual Screening: An Alternative or Complement to High Throughput Screening? Proceedings of the Workshop New Approaches in Drug Design and Discovery, special topic Virtual Screening, pp. 209-230, Springer, The Netherlands.
27. Chen, H., Zhang, Y.-H., Mutlib, A. E., and Zhong, M. (2006) Application of on-line electrochemical derivatization coupled with high performance liquid chromatography electrospray ionization mass spectrometry for detection and quantitation of (p-chlorophenyl) aniline in biological samples. Anal. Chem. 78, 2413-2421.
28. Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P., and Shimada, T. (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7, 103-113. (Pubitemid 27261842)
29. Wrighton, S. A., Stevens, J. C., Becker, G. W., and Vandenbranden, M. (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245. (Pubitemid 23291309)
30. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994) Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423. (Pubitemid 24229655)
31. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B., and Ingelman- Sundberg, M. (1999) Interindividual differences in hepatic expression of CYP 3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205.
32. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., and Hall, S. D. (2001) Sequence diversity in CYP 3A promoters and characterization of the genetic basis of polymorphic CYP 3A5 expression. Nat. Genet. 27, 383-391. (Pubitemid 32268418)
33. Schuetz, E. D., Schinkel, A. H., Relling, M. V., and Schuetz, J. D. (1996) P-Glycoprotein: a major determinant of rifampin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 93, 4001-4005.
34. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05- Å resolution. J. Biol. Chem. 279, 38091-38094.
35. Mutlib, A. E., Talaat, R. E., Slatter, J. G., and Abbott, F. S. (1990) Formation and reversibility of S-linked conjugates of N-(1-methyl- 3,3 diphenylpropyl) isocyanate, an in vivo metabolite of N-(1-methyl- 3, 3-diphenylpropyl) formamaide in rats. Drug Metab. Dispos. 18, 1038-1045.
36. Jochheim, C. M., Davis, M. R., Ballie, K. M., Ehlhardt, W. J., and Ballie, T. A. (2002) Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate. Chem. Res. Toxicol. 15, 240-248.
37. Baillie, T. A., and Slatter, G. (1991) Glutathione: A vehicle for the transport of chemically reactive metabolites in vivo. Acc. Chem. Res. 24, 264-270.
38. Baillie, T. A., and Kassahun, K. (1994) Reversibility in glutathioneconjugate formation. Adv. Pharmacol. 27, 163-181-28
39. Brown, W. E., Green, A. H., Cedel, T. E., and Cairns, J. (1987) Biochemistry of protein-isocyanate interactions: a comparison of the effects of aryl vs. alkyl isocyanates. Environ. Health. Perspect. 72, 5-11.
40. Davis, M. R., Kassahun, K., Jochheim, C. M., Brandt, K., and Baillie, T. A. (1993) Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N, N′-bis(2- chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vivo. Chem. Res. Toxicol. 6, 376-383. (Pubitemid 23146603)
41. Guan, X., Hoffman, B., McFarland, D. C., Gilkerson, K. K., Dwivedi, C., Erickson, A. K., Bebensee, S., and Pellegrini, J. (2002) Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line. Drug Metab. Dispos. 30, 331-335. (Pubitemid 34175026)
42. Gold, L. S., Manley, N. B., Slowe, T. H., Garfinkel, G. B., Rohrbach, L., and Ames, B. N. (1993) The fifth plot of the carcinogengenic potency database: results of animal bioassays published in general literature through 1988 and by the national toxicology program through 1989. Environ. Health Perspect. 100, 65-168. (Pubitemid 23197094)
43. Bus, J. S., and Popp, J. A. (1987) Perspectives on the mechanism of action of the splenic toxicity of aniline and structurally-related compounds. Food Chem. Toxicol. 25, 619-626.
44. Harrison, J. H., and Jollow, D. J. (1986) Role of aniline metabolites in aniline-induced hemolytic anemia. J. Pharmacol. Exp. Ther. 238, 1045-1054.
45. Ehlhardt, W. J., Woodland, J. M., Worzalla, J. F., Bewley, J. R., Grindey, G. B., Todd, G. C., Toth, J. E., and Howbert, J. J. (1992) Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas. Chem. Res. Toxicol. 5, 667-673.